Once-Daily Pill for Adults with Parkinson’s Disease
Juvmo (tavapadon) — selective D1/D5 dopamine agonist for Parkinson’s disease in adults
Medcelerator Brief
This is for adults with Parkinson’s disease — and caregivers — who need a labelled once-daily oral option that can be used with or without levodopa. It explains FDA approval of Juvmo (tavapadon) on 25 September 2026, the TEMPO-1/2/3 studies (NCT04201093, NCT04223193, NCT04542499), the label titration to a 5–15 mg maintenance dose, key safety warnings (low blood pressure, impulse-control urges, hallucinations, dyskinesia), and how to talk with a movement-disorder clinician when US supply starts — without treating a US bottle as another country’s carton or assuming every plan pays. Authorized is not funded.
Juvmo is a once-daily oral selective partial agonist at dopamine D1 and D5 receptors (tavapadon) tablet. On 25 September 2026, FDA approved Juvmo for the treatment of Parkinson’s disease (PD) in adults (FDA Novel Drug Approvals for 2026 row #43; US Prescribing Information revised 9/2026). It can be taken with or without food, and the labelled indication covers use with or without concomitant levodopa. Marketed by AbbVie Inc. (Cerevel Therapeutics LLC, an AbbVie company). This is not a cure, not a replacement for every other Parkinson’s medicine by default, and not established in children.
Distinct path — not this carton: Most older oral dopamine agonists primarily target D2/D3 receptors. Juvmo is labelled as a non-ergot selective D1/D5 partial agonist. Compare each medicine’s label with the movement-disorder clinic; products are not interchangeable by brand name alone.
Where this is taking place
Commercial labelled door today: United States — FDA approval 25 Sep 2026 for Parkinson’s disease in adults. AbbVie company announcement (28 Sep 2026): expects US commercial availability in October 2026. Patient access support framing on company materials points to AbbVie.com/PatientAccessSupport. Product information site named on the Patient Information: www.JUVMO.com; company contact on Patient Information 1-888-817-4847. Suspected adverse reactions: AbbVie 1-800-633-9110 or FDA MedWatch 1-800-FDA-1088.
Outside the United States: As of this draft, Health Canada, EMA/EC, MHRA, TGA, PMDA/MHLW, Swissmedic, and NMPA authorisation for Juvmo / tavapadon not confirmed on sources used here. A US bottle is not another country’s label. Do not import on your own.
TEMPO program (USPI Studies 1–3):
- Study 1 / TEMPO-1 — NCT04201093 — early PD without concomitant levodopa; fixed 5 mg or 15 mg vs placebo.
- Study 2 / TEMPO-2 — NCT04223193 — early PD without concomitant levodopa; flexible 5–15 mg vs placebo.
- Study 3 / TEMPO-3 — NCT04542499 — PD with concomitant fixed-dose levodopa and motor fluctuations; flexible 5–15 mg vs placebo.
Company materials also describe an open-label extension (TEMPO-4). Trial geography and completed enrolment support the label conversation — they are not an automatic walk-in door for every newly labelled commercial starter outside US distribution.
The practical US door is a neurologist / movement-disorder clinician who can confirm idiopathic PD, review other dopaminergic medicines and CYP3A interacting drugs, supervise the multi-week titration, and watch for orthostatic symptoms, impulse-control behaviours, hallucinations, and dyskinesia.
Approval matrix
| Regulator | Status | Date | Notes |
|---|---|---|---|
| FDA (United States) | Approved — Novel Drug Approvals 2026 #43 | 25 Sep 2026 | Adults with Parkinson’s disease. USPI Revised 9/2026. Oral once daily; maintenance 5 mg, max 15 mg. TEMPO Studies 1–3. NDA ApplNo / DailyMed setid not yet posted at scan time — use AbbVie USPI PDF + clinic label when Drugs@FDA indexes. |
| Health Canada | Not confirmed | — | — |
| EMA / European Commission | Not confirmed | — | — |
| MHRA (UK) | Not confirmed | — | — |
| TGA (Australia) | Not confirmed | — | — |
| PMDA / MHLW (Japan) | Not confirmed | — | — |
| Swissmedic | Not confirmed | — | — |
| NMPA (China) | Not confirmed | — | — |
Access by country
- United States: Ask a movement-disorder / neurology clinic about labelled Juvmo if the person is an adult with Parkinson’s disease. Path: confirm diagnosis → review blood-pressure symptoms, mental-health history, impulse-control history, and all medicines (especially CYP3A inhibitors/inducers) → start with the titration pack toward 5 mg once daily, then adjust up to 15 mg if needed → arrange AbbVie patient-access support if the clinic uses that channel when US supply is live. No list price or copay dollars in this article.
- Canada / EU / UK / Australia / Japan / other countries: Authorisation not confirmed here. Ask the local clinician what legal paths exist — without treating a US bottle as a foreign carton.
- If your regulator has not authorised it: do not import on your own.
Who is eligible
United States (USPI, Revised 9/2026):
- Indication: Treatment of Parkinson’s disease in adults.
- With or without levodopa: Labelled for use as monotherapy in early PD (Studies 1–2) and as adjunct to levodopa in people with motor fluctuations (Study 3).
- Dose: Oral once daily, with or without food. Titration from 0.25 mg toward maintenance 5 mg once daily; may increase in 5 mg steps about every 15 days to a maximum of 15 mg once daily based on tolerability and response (USPI Table 1). Titration pack recommended to reach the 5 mg maintenance dose.
- Contraindications: None (USPI §4).
- Pediatrics: Safety and effectiveness not established.
- Geriatrics: Of 1,279 treated patients, 54% were ≥65 and 13% ≥75; age ≥65 increases hallucination risk.
- CYP3A: Avoid strong/moderate CYP3A inhibitors during titration; adjust maintenance frequency if inhibitors are started later. Avoid strong CYP3A inducers; long-term moderate inducers require increased dosing frequency (see USPI Tables 2–3).
Not labelled on sources confirmed for this draft:
- Children.
- EU, UK, Canadian, Japanese, Australian, Swiss, or Chinese Juvmo marketing authorisations.
- Self-switching from another dopamine agonist without a clinician reading each label.
What the pivotal study showed (TEMPO / USPI Studies 1–3)
Use the USPI for a prescription conversation. Company press and journals are supportive reading.
Study 1 — NCT04201093 (without levodopa): 529 randomized to Juvmo 5 mg, 15 mg, or placebo once daily. Primary: change in MDS-UPDRS Part II at Week 26. LS mean change: −1.6 (5 mg), −1.7 (15 mg), +0.9 (placebo); both doses vs placebo p < 0.0001.
Study 2 — NCT04223193 (without levodopa): 304 randomized to flexible Juvmo 5–15 mg or placebo. Part II LS mean change at Week 26: −1.5 vs 0.0; difference −1.5 (95% CI −2.4, −0.6); p = 0.0007.
Study 3 — NCT04542499 (with concomitant levodopa): 507 randomized to flexible Juvmo 5–15 mg or placebo on top of stable levodopa (≥400 mg/day). Primary: change in total daily ON time without troublesome dyskinesia at Week 26: +1.7 hours (Juvmo) vs +0.6 hours (placebo); difference 1.1 hours (95% CI 0.6, 1.7); p < 0.0001. Key secondary OFF time: −1.9 vs −0.9 hours; p = 0.0006.
How it is taken
| Item | On-source detail (USPI) |
|---|---|
| Drug | Juvmo (tavapadon) tablets — 0.25, 1, 5, 10, 15 mg |
| Schedule | Once daily orally, with or without food |
| Titration | Days 1–40 stepwise from 0.25 mg to 3 mg, then 5 mg maintenance from Day 41 (Table 1); titration pack recommended |
| Maintenance / max | 5 mg once daily; may increase by 5 mg ~every 15 days to max 15 mg once daily |
| Missed dose | Take same day when remembered; do not double; do not take a missed dose the next day |
| CYP3A caveats | Separate frequency rules for inhibitors/inducers — see USPI §§2.2–2.3 |
NDCs on USPI include bottles of 30 for 5 mg (0074-6105-30), 10 mg (0074-6210-30), 15 mg (0074-6315-30), and titration pack (0074-6090-40).
Safety (what the label puts first)
USPI Warnings and Precautions lead with:
- Hypotension / orthostatic hypotension — monitor especially during dose escalation; rise slowly.
- Impulse control / compulsive behaviours — gambling, sexual, spending, binge eating urges; consider dose reduction or stopping.
- Hallucinations and psychotic-like behaviour — higher risk with age ≥65 and with strong CYP3A inhibitors in maintenance; weigh risks if major psychotic disorder.
- Dyskinesia — may cause or worsen; consider lowering Juvmo or other dopaminergic doses.
Most common adverse reactions (≥5%):
- Without levodopa: nausea, headache, dizziness, fatigue, dysgeusia, vomiting, dry mouth, anxiety.
- With levodopa: nausea, dyskinesia, dizziness, headache, hallucinations, orthostatic hypotension.
How to talk to a doctor
Bring: Parkinson’s diagnosis and stage, current levodopa and other PD medicines (doses and timing), ON/OFF diary if you keep one, blood-pressure symptoms when standing, any history of hallucinations or impulse-control behaviours, and a full medication list (especially antifungals, some antibiotics, seizure medicines, St. John’s wort — CYP3A relevant). Ask: “Am I in the FDA-labelled adult Juvmo population, and should we start the titration pack toward 5 mg with or without my current levodopa?” Ask how AbbVie patient-access support fits the clinic’s path when US supply starts. Do not start, stop, or combine dopaminergic medicines without the clinic.
Research and regulatory team
- Global principal TEMPO trial investigator named on AbbVie approval materials: Hubert Fernandez, M.D., professor of neurology, Cleveland Clinic Lerner College of Medicine.
- USPI marketed by: AbbVie Inc., North Chicago, IL 60064 (Cerevel Therapeutics, LLC, an AbbVie company — trademark framing on USPI).
- FDA Novel Drug Approvals 2026: row #43, approval date 25 Sep 2026, use line: treat Parkinson’s disease in adults.
- Patient community voice on company materials: The Michael J. Fox Foundation for Parkinson’s Research (organisational comment — not a prescribing clinic).
Canada zoom: authorisation not confirmed
Juvmo / tavapadon authorisation not confirmed in Canada on sources used here. A US prescription or US bottle is not a Health Canada Product Monograph. Ask the Canadian movement-disorder clinic what legal options exist while there is no Canadian Juvmo label. Do not import a US bottle on your own.
Bottom line
Juvmo is a US-labelled once-daily oral selective D1/D5 dopamine agonist for adults with Parkinson’s disease, approved 25 September 2026. It can be used with or without levodopa, after a structured titration to 5–15 mg. The near-term path is a movement-disorder clinic prescription when US commercial supply is live — not a DIY import, and not an assumption that every country or plan will fund it.
Primary sources
- FDA Novel Drug Approvals for 2026 — Juvmo #43
- Juvmo (tavapadon) Prescribing Information (AbbVie; Revised 9/2026)
- ClinicalTrials.gov NCT04201093 (TEMPO-1 / Study 1)
- ClinicalTrials.gov NCT04223193 (TEMPO-2 / Study 2)
- ClinicalTrials.gov NCT04542499 (TEMPO-3 / Study 3)
- AbbVie company announcement 28 Sep 2026 (company — not the regulator)
How do I get this?
The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.
General resources for further research
General registries and programmes. They are not routes to this treatment; use them to research further.
United States · Trial registry
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
Organizations and researchers
- Sponsor
Primary on this article
AbbVie Inc.
USPI marketer / TEMPO CT.gov lead-sponsor family — Juvmo (not Cerevel SPONSOR; not D2/D3 agonists)
Sites / historical
Other organizations
- Other
The Michael J. Fox Foundation for Parkinson’s Research
Patient-community voice quoted on company Juvmo approval materials — not a prescribing clinic
People
Hubert Fernandez, M.D.
TEMPO global principal investigator (quoted on AbbVie approval materials; Cleveland Clinic)
MoreLess
Named in AbbVie Juvmo (tavapadon) FDA-approval company materials (28 September 2026) as global principal TEMPO trial investigator, with affiliation professor of neurology at the Cleveland Clinic Lerner College of Medicine. Named with affiliation on company materials — not a ClinicalTrials.gov overall official on TEMPO-1/2/3 (those records list AbbVie study directors, not named individuals).